Processa Pharmaceuticals (NASDAQ: PCSA) CFO buys 2,324 company shares

Rhea-AI Filing Summary

Processa Pharmaceuticals, Inc. Chief Financial Officer Russell Skibsted reported an open-market purchase of company stock. He bought 2,324 shares of Common Stock at a price of $2.535 per share on March 31, 2026, and now directly holds 2,324 shares following this transaction.

Insider Trade Summary

Net Buyer: 2,324 shares ($5,891)

Net Buy 1 txn

Insider SKIBSTED RUSSELL

Role Chief Financial Officer

Bought 2,324 shs ($6K)

Type	Security	Shares	Price	Value
Purchase	Common Stock	2,324	$2.535	$6K

Holdings After Transaction: Common Stock — 2,324 shares (Direct)

Footnotes (1)

Key Figures

Shares purchased: 2,324 shares Purchase price: $2.535 per share Shares owned after transaction: 2,324 shares

3 metrics

Shares purchased 2,324 shares Open-market purchase on March 31, 2026

Purchase price $2.535 per share Price paid for Common Stock

Shares owned after transaction 2,324 shares Direct ownership following reported trade

Key Terms

open-market purchase, Common Stock, Form 4

3 terms

open-market purchase financial

"The transaction is classified as an open-market purchase of Common Stock."

An open-market purchase is when an investor or a company buys shares on a public stock exchange at the going market price, rather than through a private deal. It matters to investors because these purchases change how many shares are available, can push the stock price up or signal confidence from large buyers, and often affect per-share metrics like earnings—think of it like someone buying lots of apples off a grocery shelf, reducing supply and potentially raising the price.

Common Stock financial

"The insider acquired 2,324 shares of Common Stock at $2.535 per share."

Common stock represents ownership shares in a company, giving investors a stake in its success and a say in important decisions through voting rights. It is the most common type of stock traded on markets and can provide income through dividends, as well as potential for value growth. For investors, holding common stock means sharing in the company’s profits and risks.

Form 4 regulatory

"The insider transaction is reported on a Form 4 filing."

Form 4 is a official document that company insiders, such as executives or major shareholders, file with regulators whenever they buy or sell company shares. It provides transparency about how those with inside knowledge are trading, helping investors see if insiders are confident in the company's prospects or may be selling for personal reasons. This information can influence investor decisions by revealing insiders' perspectives on the company's value.

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

SKIBSTED RUSSELL

(Last) (First) (Middle)

C/O PROCESSA PHARMACEUTICALS, INC.

601 21ST STREET SUITE 300

(Street)

VERO BEACH FLORIDA 32960

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Processa Pharmaceuticals, Inc. [ PCSA ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Financial Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
03/31/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	03/31/2026		P		2,324	A	$2.535	2,324	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

	/s/ Russell Skibsted by John J. Wolfel, as Attorney-in-Fact	04/01/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What insider transaction did PCSA’s CFO report on this Form 4?

Processa Pharmaceuticals’ CFO reported an open-market purchase of 2,324 shares of Common Stock. The shares were acquired at a price of $2.535 per share, and this filing reflects his updated direct ownership position after the transaction.

How many Processa Pharmaceuticals (PCSA) shares did the CFO buy?

The CFO of Processa Pharmaceuticals bought 2,324 shares of Common Stock. This entire amount represents his direct holdings after the transaction, meaning his reported post-transaction ownership is 2,324 shares according to the Form 4 data.

At what price did PCSA’s CFO purchase the shares reported in this filing?

The CFO purchased Processa Pharmaceuticals Common Stock at $2.535 per share. This price applies to all 2,324 shares acquired in the open-market transaction reported, providing a clear view of the insider’s entry price for this purchase.

Was the PCSA CFO’s Form 4 transaction a buy or a sell?

The transaction reported by Processa Pharmaceuticals’ CFO was a buy. Specifically, it was classified as an open-market purchase of 2,324 shares of Common Stock, with no sales or derivative exercises disclosed in this Form 4.

How many PCSA shares does the CFO own after this reported transaction?

After the reported purchase, the CFO directly owns 2,324 shares of Processa Pharmaceuticals Common Stock. The Form 4 shows this total as his direct holdings following the transaction, with no additional derivative positions listed.